The drug is indicated for use as a treatment of infections caused by aerobic Gram-negative bacteria
News
NICE backing for AZ’ Tagrisso
The Institute has endorsed the drug for first-line treatment of adults with locally-advanced or EGFR mutation-positive NSCLC
AZ resumes trial of COVID-19 vaccine
The move follows a green light by the UK’s MHRA
Gilead to buy Immunomedics for $21bn
The move adds Trodelvy, a first-in-class antibody-drug conjugate approved to treat triple-negative breast cancer, to the drugmaker’s portfolio
ABPI welcomes UK-Japan trade agreement
Under the deal the UK and Japan will incorporate functions of the existing EU/Japan Mutual Recognition Agreement for medicines
NICE backs Portola’s Ondexxya
The drug’s use has, however, been restricted to reversing anticoagulation from apixaban or rivaroxaban in adults with life threatening or uncontrolled bleeding in the gastrointestinal tract
AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps
The drug reduced the size of nasal polyps and reduced nasal blockage
Research backs use of liquid biopsy for personalised cancer care
The blood test reliably picks up mutations in breast cancer and matches women to different targeted treatments, researchers said
NIHR, UKRI fund eight new coronavirus research projects
The projects are investigating different aspects of virus transmission in the hope that findings will better inform policy decisions on prevention and containment
US expands scope of Trelegy Ellipta to include asthma
Trelegy Ellipta is now the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
EU review extended for BioMarin’s gene therapy Valrox
The EMA has asked for full data from an ongoing Phase III study of the treatment in patients with severe haemophilia A
Pfizer, BioNTech could supply EU with 300m doses of SARS-CoV-2 vaccine
The proposed deal covers the initial supply of 200 million doses and an option to purchase an additional 100 million, with deliveries starting by the end of 2020, if the vaccine is approved
ATTC Network gets further investment of £9.5m
The UK government grant will support new and existing advanced therapy projects until March 2022
NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
NAO calls for cross-government initiative on childhood obesity
The move follows a report which found it is not clear that the current programme will be able to drive the progress needed in the timescale available
